Alkermes plc expanded its board of directors from ten to eleven members and appointed Anne C. Whitaker as an independent director, effective September 14, 2026. Ms. Whitaker will receive standard annual cash retainers and equity grants per the company's proxy statement, plus a new director award valued at $600,000 comprising stock options and restricted stock units vesting over three years. She brings extensive biopharmaceutical executive experience, having previously served as CEO of Aerami Therapeutics, Novoclem Therapeutics, and Synta Pharmaceuticals Corporation. Alkermes plc is a global biopharmaceutical company that develops innovative medicines in the field of neuroscience.
